Back to search

Peptide record

TPDB40915

mtp1 Anticancer standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40915
mtp1
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 12-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
DGDWDAWTRETS
Physicochemical Analysis
C61H83N17O24
NCQHILKMFPYV
D
1438.43
3.50
1
4
3
-3
3.07
-1.758
8.33
Mammalian: 1.1 hour Yeast: 3 min E.coli: >10 hour
11000
764.72
3
Residue Composition
number
1
A
1
R
0
N
3
D
0
C
1
E
0
Q
1
G
0
H
0
I
0
L
0
K
0
M
0
F
0
P
1
S
2
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 1 N: 0 D: 3 C: 0 E: 1 Q: 0 G: 1 H: 0 I: 0 L: 0 K: 0 M: 0 F: 0 P: 0 S: 1 T: 2 W: 2 Y: 0 V: 0
Chemical Descriptors
12
C61H83N17O24
1438.43
3.50
-3
3.07
-1.758
Free
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

33.6% decrease in cell viability at 10 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

30.2 % decrease in cell viability at 10 µM
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

17.4% decrease in cell viability at 10 µM
Anticancer

Target

Lung Cancer
A-549
Lung

Assay & Model

MTS assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023